The dawn of a new era: targeting the “undruggables” with antibody-based therapeutics
The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …
Evolution of cancer pharmacological treatments at the turn of the third millennium
The medical history of cancer began millennia ago. Historical findings of patients with
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Abstract Introduction The Fibroblast Growth Factor Receptor (FGFR) family consists of
Tyrosine Kinase Receptors (TKR) involved in several biological functions. Recently …
Tyrosine Kinase Receptors (TKR) involved in several biological functions. Recently …
Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
Abstract Background Receptor tyrosine kinases (RTKs) are signaling enzymes responsible
for the transfer of Adenosine triphosphate (ATP) γ-phosphate to the tyrosine residues …
for the transfer of Adenosine triphosphate (ATP) γ-phosphate to the tyrosine residues …
A systematic study on chitosan-liposome based systems for biomedical applications
The advent of liposome technology with its unique features has led researchers to work
relentlessly on the successful development of novel drug delivery vehicles based on …
relentlessly on the successful development of novel drug delivery vehicles based on …
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters
The development of multidrug resistance (MDR) to chemotherapy remains a major
challenge in the treatment of cancer. Numerous mechanisms have been recognized that …
challenge in the treatment of cancer. Numerous mechanisms have been recognized that …
Anti-tumor activity of novel nimotuzumab-functionalized gold nanoparticles as a potential immunotherapeutic agent against skin and lung cancers
M Anisuzzman, V Komalla, MAM Tarkistani… - Journal of Functional …, 2023 - mdpi.com
The epidermal growth factor receptor (EGFR) is vital for many different types of cancer.
Nimotuzumab (NmAb), an anti-EGFR monoclonal antibody (mAb), is used against some of …
Nimotuzumab (NmAb), an anti-EGFR monoclonal antibody (mAb), is used against some of …
[HTML][HTML] Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity
DVT Catenacci - Molecular oncology, 2015 - Elsevier
The promise of 'personalized cancer care'with therapies toward specific molecular
aberrations has potential to improve outcomes. However, there is recognized heterogeneity …
aberrations has potential to improve outcomes. However, there is recognized heterogeneity …
The past, present, and future of chemotherapy with a focus on individualization of drug dosing
L DeRidder, DA Rubinson, R Langer… - Journal of Controlled …, 2022 - Elsevier
While there have been rapid advances in developing new and more targeted drugs to treat
cancer, much less progress has been made in individualizing dosing. Even though the …
cancer, much less progress has been made in individualizing dosing. Even though the …
Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia
Oligonucleotide aptamers can specifically bind biomarkers on cancer cells and can be
readily chemically modified with different functional molecules for personalized medicine. To …
readily chemically modified with different functional molecules for personalized medicine. To …